Dr. El-Khoueiry on Choosing Between Immunotherapy Agents and TKIs in HCC
July 19th 2019Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses choosing between immunotherapy agents and TKIs in hepatocellular carcinoma (HCC).
Read More
Dr. El-Khoueiry on Choosing Between Lenvatinib and Sorafenib in HCC
June 12th 2019Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, distinguishes between lenvatinib and sorafenib for the frontline treatment of advanced hepatocellular carcinoma.
Read More
Dr. El-Khoueiry on Evolving Role of Immunotherapy in HCC
October 19th 2016Anthony B. El-Khoueiry, MD, associate professor of Clinical Medicine, USC Norris Comprehensive Cancer Center, discusses the role that immunotherapy currently plays, and will continue to play, in the treatment landscape of hepatocellular carcinoma (HCC).
Read More
Dr. El-Khoueiry on the Rationale for Evaluating Nivolumab in Advanced HCC
September 14th 2016Anthony B. El-Khoueiry, MD, associate professor of Clinical Medicine, USC Norris Comprehensive Cancer Center, discusses the rationale for evaluating nivolumab in advanced hepatocellular carcinoma (HCC).
Read More